Following on from information provided to NICE by the company in March 2017, the appraisal of Glioblastoma (recurrent) – nivolumab was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 998 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 November 2022 | Discontinued. Following on from information provided to NICE by the company in March 2017, the appraisal of Glioblastoma (recurrent) – nivolumab was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 10 May 2017 | Suspended. The company have advised NICE that CheckMate -143, a randomised phase 3 clinical trial evaluating the efficacy and safety of nivolumab in patients with first recurrence of glioblastoma multiforme, did not meet its primary endpoint of improved overall survival compared to bevacizumab monotherapy and therefore they will not be seeking regulatory approval from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes. In addition, the company has ongoing clinical trials in newly-diagnosed glioblastoma multiforme (CheckMate -498 and CheckMate -548). These trials are moving forward as planned. |
| 22 July 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual